London-based LabGenius, which uses AI and “robotic automation” for protein drug discovery, raises $10M Series A led by Lux Capital and Obvious Ventures
LabGenius, a London-based startup applying AI and “robotic automation” to protein drug discovery, has raised $10 million in Series A funding.
Synthetic biology, robotic automation, & ML, for full-stack protein engineering: @labgeni_us just raised 10M$, with our own @airstreetcap in the round, and @matthewclifford @NathanBenaich and @pichette involved :) Excited by this combination! https://techcrunch.com/... https://tw…
1/ Great companies are NOT built by individuals, they're built by teams driven by a shared passion, a shared mission, a shared purpose. The @labgeni_us investor base is an integral part of our team and today, it got a lot bigger! https://techcrunch.com/... https://www.forbes.com/…
As our 1st investment out of our newly opened London office >1yr ago, @pichette and I couldn't be more thrilled to renew our partnership with @jejfield and the @labgeni_us team to redefine protein therapy development with ML-driven experimentation. https://twitter.com/...
LabGenius are working on AI driven drug discovery and have an extremely special team. I took part in their $10m A round and you can check out more about them here and in the thread below. https://golden.com/... https://twitter.com/...